Cytokinetics Incorporated's stock surged 5.64% during intraday trading on Friday. The significant move follows the successful closure of a major capital raise and continued positive momentum from recent clinical developments.

The company announced the closing of an underwritten public offering of over 11.3 million shares of its common stock at $71.00 per share, raising gross proceeds of approximately $805 million. The offering included the full exercise of the underwriters' option to purchase additional shares, indicating strong institutional demand.

Investor confidence is further bolstered by the company's recent announcement that its Phase 3 ACACIA-HCM trial for aficamten achieved dual primary endpoints in treating symptomatic non-obstructive hypertrophic cardiomyopathy. Additionally, the company reported strong early commercial traction for its drug MYQORZO (aficamten) in the first quarter. The combination of a strengthened balance sheet from the offering and validated clinical progress appears to be driving the stock's upward movement.